• The Case For Optimism In The U.S. Biosimilar Market

    In the U.S., it is estimated that biosimilars can save the healthcare system approximately $150 billion over the next five to 10 years. In this op-ed, Amgen's Chad Pettit shares why the U.S. has cause to be optimistic about the competition emerging in the U.S. 

  • 5 Operational Priorities For Pharmas In The Wake Of COVID-19

    Consider Gilead’s ramp-up of remdesivir under FDA Emergency Use Authorization, or the efforts of companies racing to bring vaccines and therapeutics for COVID-19 through clinical development, safety and efficacy trials at speeds not seen before. The analogy of changing a tire while driving the vehicle is well known — now picture doing so at 7,000 rpm!

  • Maybe Biosimilar Applicants Should Dance After All

    The decision to engage in the BPCIA patent dance with a reference product sponsor is rarely black and white. Early dismissals in cases like Eagle v. Slayback and Amgen v. Coherus are just one factor a biosimilar applicant should consider.

  • Old Drug, New Tricks: Will The BPCIA Drive Generic Competition For Insulins?

    High demand, few suppliers, and soaring prices point to the need for more generic competition in the insulin market. This article discusses recent changes to the legal and regulatory framework governing insulin approval that might facilitate such entry.

  • Africa’s Biosimilar Landscape: Outlook & Current Challenges

    Emerging markets, particularly Africa, represent an interesting case study for biosimilars. With a young population of more than 1.3 billion, Africa’s economy is the world's second-fastest growing, and the GDP is expected to grow to 3.9 percent in 2020 and 4.1 percent in 2021, according to the African Development Bank.

  • A New Guide For Promotional Labeling And Advertising Of Biosimilar Products

    This article will outline the central components of new FDA guidance on promotional labeling and advertising considerations for biological reference and biosimilar products. While such materials are overseen by the FDA, the article also explores an alternative method of challenging claims of misinformation and other forms of unfair competition that may impact the biosimilar space moving forward.

  • Can Biosimilars Be The Bridge To More Widespread Continuous Bioprocessing?

    This article will examine the relationship between improved continuous manufacturing (CM) and biosimilar development, paying particular attention to the reasons why biosimilars are especially promising candidates for CM development and innovation.






The COVID-19 pandemic has thrown the entire pharmaceutical industry, as well as patients, providers, and sites of care for a loop. Though small molecule novel treatments and generics have seen much more pronounced impacts from market shut-downs and supply-chain disruptions, the biologics and biosimilars industry has also been striving to understand how the pandemic will alter availability and usage of biologic products. This collection of articles surveys a wide array of considerations facing biopharma and biosimilar companies, including the pandemic's impact on regulatory interactions, product supply and demand, materials sourcing, and market access and uptake.

More Content Collections